Literature DB >> 22543224

Clinical spectrum, risk factors and outcome of immune reconstitution inflammatory syndrome in patients with tuberculosis-HIV coinfection.

William Worodria1, Joris Menten, Marguerite Massinga-Loembe, Doreen Mazakpwe, Danstan Bagenda, Olivier Koole, Harriet Mayanja-Kizza, Luc Kestens, Roy Mugerwa, Peter Reiss, Robert Colebunders.   

Abstract

BACKGROUND: Here, we aimed to determine the clinical spectrum, predictors and outcomes of paradoxical tuberculosis-immune reconstitution inflammatory syndrome (TB-IRIS) in a resource-limited setting.
METHODS: In a prospective cohort, we studied 254 patients with tuberculosis and HIV coinfection commencing antiretroviral therapy (ART). We identified patients with TB-IRIS using the International Network for Studies Against HIV-Associated IRIS (INSHI) case definition. Risk factors and clinical outcomes of TB-IRIS were determined and reported.
RESULTS: A total of 53 (21%) patients developed TB-IRIS a median of 2 weeks (IQR 12-22 days) after starting ART. The majority of the patients (70%) with TB-IRIS had extrapulmonary manifestations of TB-IRIS. In a multiple logistic regression model, baseline haemoglobin <100 g/l (OR 2.23 [95% CI 1.08-4.60]; P=0.031) and baseline CD4(+) T-cell count <50 cells/μl (OR 4.13 [95% CI 1.80-9.51]; P=0.001) were significant predictors of IRIS. Seven additional patients fulfilled all INSHI criteria of TB-IRIS but had the episode of TB-IRIS later than 3 months after ART start.
CONCLUSIONS: TB-IRIS was a frequent reason for clinical deterioration among patients with TB commencing ART but was not a primary contributor to mortality. Patients with advanced CD4 depletion and anaemia were at increased risk of TB-IRIS. Some patients developed late-onset TB-IRIS and/or a recurrent TB-IRIS episode.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22543224     DOI: 10.3851/IMP2108

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  16 in total

1.  Immune reconstitution disorders in patients with HIV infection: from pathogenesis to prevention and treatment.

Authors:  C C Chang; V Sheikh; I Sereti; M A French
Journal:  Curr HIV/AIDS Rep       Date:  2014-09       Impact factor: 5.071

Review 2.  Tobacco smoking effect on HIV-1 pathogenesis: role of cytochrome P450 isozymes.

Authors:  Anusha Ande; Carole McArthur; Anil Kumar; Santosh Kumar
Journal:  Expert Opin Drug Metab Toxicol       Date:  2013-07-04       Impact factor: 4.481

3.  Antigen-specific interferon-gamma responses and innate cytokine balance in TB-IRIS.

Authors:  Odin Goovaerts; Wim Jennes; Marguerite Massinga-Loembé; Ann Ceulemans; William Worodria; Harriet Mayanja-Kizza; Robert Colebunders; Luc Kestens
Journal:  PLoS One       Date:  2014-11-21       Impact factor: 3.240

4.  Opportunistic diseases diminish the clinical benefit of immediate antiretroviral therapy in HIV-tuberculosis co-infected adults with low CD4+ cell counts.

Authors:  William Worodria; Victor Ssempijja; Coleen Hanrahan; Richard Ssegonja; Abdallah Muhofwa; Doreen Mazapkwe; Harriet Mayanja-Kizza; Steven J Reynolds; Robert Colebunders; Yukari C Manabe
Journal:  AIDS       Date:  2018-09-24       Impact factor: 4.177

5.  Lower Pre-Treatment T Cell Activation in Early- and Late-Onset Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome.

Authors:  Odin Goovaerts; Wim Jennes; Marguerite Massinga-Loembé; Pascale Ondoa; Ann Ceulemans; Chris Vereecken; William Worodria; Harriet Mayanja-Kizza; Robert Colebunders; Luc Kestens
Journal:  PLoS One       Date:  2015-07-24       Impact factor: 3.240

6.  LPS-binding protein and IL-6 mark paradoxical tuberculosis immune reconstitution inflammatory syndrome in HIV patients.

Authors:  Odin Goovaerts; Wim Jennes; Marguerite Massinga-Loembé; Ann Ceulemans; William Worodria; Harriet Mayanja-Kizza; Robert Colebunders; Luc Kestens
Journal:  PLoS One       Date:  2013-11-28       Impact factor: 3.240

7.  Neutrophil Activation and Enhanced Release of Granule Products in HIV-TB Immune Reconstitution Inflammatory Syndrome.

Authors:  Justine K Nakiwala; Naomi F Walker; Collin R Diedrich; William Worodria; Graeme Meintjes; Robert J Wilkinson; Harriet Mayanja-Kizza; Robert Colebunders; Luc Kestens; Katalin A Wilkinson; David M Lowe
Journal:  J Acquir Immune Defic Syndr       Date:  2018-02-01       Impact factor: 3.731

8.  Paradoxical tuberculosis immune reconstitution inflammatory syndrome (TB-IRIS) in HIV patients with culture confirmed pulmonary tuberculosis in India and the potential role of IL-6 in prediction.

Authors:  Gopalan Narendran; Bruno B Andrade; Brian O Porter; Chockalingam Chandrasekhar; Perumal Venkatesan; Pradeep A Menon; Sudha Subramanian; Selvaraj Anbalagan; Kannabiran P Bhavani; Sathiyavelu Sekar; Chandrasekaran Padmapriyadarshini; Satagopan Kumar; Narayanan Ravichandran; Krishnaraj Raja; Kesavamurthy Bhanu; Ayyamperumal Mahilmaran; Lakshmanan Sekar; Alan Sher; Irini Sereti; Soumya Swaminathan
Journal:  PLoS One       Date:  2013-05-17       Impact factor: 3.240

9.  Incidence of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome and impact on patient outcome.

Authors:  Maryline Bonnet; Elisabeth Baudin; Ilesh V Jani; Elizabete Nunes; François Verhoustraten; Alexandra Calmy; Rui Bastos; Nilesh B Bhatt; Christophe Michon
Journal:  PLoS One       Date:  2013-12-18       Impact factor: 3.240

Review 10.  Integrated therapy for HIV and tuberculosis.

Authors:  Weerawat Manosuthi; Surasak Wiboonchutikul; Somnuek Sungkanuparph
Journal:  AIDS Res Ther       Date:  2016-05-12       Impact factor: 2.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.